GLP-1 Cross-Sector Digest
TL;DR
The pipeline just delivered the cycle's real surprise: Viking's maintenance data and Zealand's Phase 3 launch showed the next generation of obesity drugs is being built around adherence and tolerability, not just more weight loss. Meanwhile the commercial race keeps tilting toward Lilly — 70% of the Medicare Bridge market, 57% of the total class — and Novo's Capital Markets Day did nothing to change that, with shares falling another ~8% on the day.
The next generation is attacking the class's biggest weakness: quitting
The challengers are no longer competing on efficacy alone — they're building drugs people can actually stay on. Viking Therapeutics reported topline maintenance data for VK2735 on September 22 showing up to 97% of weight loss retained on every-other-week dosing and up to 90% on monthly dosing, with GI adverse events "comparable to placebo" — the first incretin therapy shown to hold weight loss when dosing is stretched beyond weekly (Viking VK2735 maintenance data). Shares rose as much as 36% on the print.
"These results are important as they provide a basis for improved dosing flexibility for both clinicians and their patients… Flexibility for patients and providers is paramount for achieving treatment persistence." — Viking VK2735 maintenance data
(Source: BioPharma Dive, Sep 22, 2026)
The same day, Zealand and Roche kicked off the registrational Phase 3 ZUPREME program for petrelintide — the first amylin monotherapy to reach registrational testing — with three trials totaling ~7,000 participants and a week-64 primary endpoint, pitched on "double-digit weight loss with a tolerability profile largely comparable to placebo" (Zealand/Roche ZUPREME Phase 3). This matters because discontinuation is the quiet threat to GLP-1 economics: a drug that can be dosed monthly, or tolerated for years, changes the refill base entirely. Readouts land in 2028–29, but the initiation itself validates the amylin thesis — the same class Morningstar ranks above CagriSema in Novo's own pipeline (Novo CMD reset
).
What to watch: Viking's oral VK2735 Phase 3 initiation targeted for Q4 2026 — an oral-plus-monthly-maintenance combination would be a genuinely new commercial category.
Lilly's share capture is compounding across every channel
The Lilly/Novo gap isn't narrowing anywhere you look. Tirzepatide now holds nearly 57% of the total GLP-1 market versus semaglutide's flat 37%, and in obesity the split is roughly 60/40 (Oral GLP-1 race). The Medicare GLP-1 Bridge — the CMS demonstration with a $50 monthly copay — has reached ~700,000 seniors, and Lilly CEO David Ricks says his company is capturing 70% of it at a net price of $245/month, which Jefferies sizes at ~$1.4B annualized today and $3–3.5B by year-end (Medicare Bridge at 700K
).
"That's very encouraging—that seniors are talking to doctors… It's very market-expansionary, which is what we had hoped." — Medicare Bridge at 700K
(Source: FiercePharma, Sep 23, 2026)
Lilly is also building for the volume: the company broke ground on a $6.5B Houston API plant the same week it confirmed Foundayo captures about 1 in 3 new oral GLP-1 starts (Oral GLP-1 race). The financial scoreboard behind this: Mounjaro plus Zepbound did $14.9B in Q2 revenue, up 136% year over year, while Novo treated ~5M obesity patients off a smaller, cheaper base.
What to watch: Q3 earnings in early-to-mid November — specifically the Bridge run-rate and whether Foundayo's new-start share converts into absolute script parity with the Wegovy pill's ~181K weekly.
Novo's reset: credible targets, no conviction
Novo's Capital Markets Day on September 21 landed as a second vote of no confidence, with shares down ~8% on the day. The 2030 ambitions — mid-single-digit top-line growth, roughly steady margins, five-plus multi-blockbusters, DKK 150B in risk-adjusted pipeline sales by 2035 — were met with Morningstar cutting its fair value estimate to DKK 275 from DKK 285 (Novo CMD reset). The stock is down roughly 74% since mid-2024 while Lilly is up ~35%.
"Mid-single-digit top-line growth through 2030 looks achievable and in line with our current projections (6% 2026-30 CAGR)." — Novo CMD reset
(Source: Morningstar, Sep 2026)
The one clinical bright spot — CagriSema beating tirzepatide in a head-to-head Type 2 diabetes trial at an estimated 12.4% weight loss — came with an asterisk: the comparison was against tirzepatide's second-lowest dose. The near-term cupboard is thin (the only other drug under FDA review is a hemophilia treatment), and Morningstar models the Wegovy pill growing to $12B by 2030 only if global prices fall ~15% annually — the "10x patients" goal is explicitly a volume-for-price trade.
What to watch: The CagriSema FDA decision in Q4 2026 — still the single hardest catalyst for the reset narrative.
The demand story keeps expanding — now in seniors
The Bridge data resolves last cycle's plateau worry, at least partially: after Walgreens flagged a "natural plateau" in Bridge uptake, Ricks put enrollment at 700,000 seniors three weeks after CMS cited 600,000 — and characterizes the flow as incremental, not cannibalized, with physicians steering the heaviest seniors to Zepbound and convenience-seekers to Foundayo (Medicare Bridge at 700K). Both oral GLP-1s hit all-time weekly script highs in the latest IQVIA read — Wegovy pill at ~181K, Foundayo at ~44K — reinforcing that the pills are broadening the class rather than splitting it (Oral GLP-1 race
).
What to watch: The January 2027 list-price cuts (Ozempic -35%, Wegovy -50%), which will reset the net-price baseline the Bridge economics are built on.
What surprised us
- Maintenance dosing is the new moat. Everyone assumed the next wave would compete on weight loss; Viking's biweekly/monthly data suggests the real differentiation is half-life and persistence — a framing that flatters VK2735's long half-life and threatens every weekly-only asset.
- The seniors market is real and Lilly-shaped. A $50-copay demonstration was supposed to be a policy experiment; instead it's a ~$3B annualized run-rate for Lilly by year-end at 70% share — market expansion, not substitution.
- Morningstar ranks zenagamtide (2029) above CagriSema (2027) in Novo's own pipeline. The most-anticipated near-term launch isn't the asset bulls should care most about — the oral-formulation amylin is. The zenagamtide Phase 3 initiation in T2D is now a standalone watch.
- Novo's CMD bright spot was blunted by dose selection. A head-to-head win that only holds against the second-lowest tirzepatide dose is the kind of detail the market catches immediately — and it explains why an 8% drawdown followed a "positive" data point.
Open threads worth a vote
[watch] Novo zenagamtide (amycretin) Phase 3 initiation in T2D](/topics/019e46ac-88a3-731f-aeee-a2d9443452d6#threads)[watch] GLP-1 majors Q3 2026 earnings: Foundayo ramp, Bridge run-rate, CagriSema launch prep](/topics/019e46ac-88a3-731f-aeee-a2d9443452d6#threads)